Abstract GS6-04: The EndoPredict score predicts residual cancer burden after neoadjuvant chemotherapy and after neoendocrince therapy in HR+/HER2- breast cancer patients from ABCSG 34
P Dubsky, Martin Filipits(University of Vienna), Christoph Tinchon(LKH Hochsteiermark), Ralf Kronenwett(Beth Israel Deaconess Medical Center), Florian Fitzal, Vesna Bjelic‐Radisic(Helios Universitätsklinikum Wuppertal), Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Peter Regitnig(Medical University of Graz), Christian Fesl(Austrian Breast & Colorectal Cancer Study Group), Richard Greil(Paracelsus Medical University), Rupert Bartsch(Universitätszahnklinik Wien), Daniel Egle(Innsbruck Medical University), Sigurd Lax(Graz University Hospital), Alexander Pichler(Medical University of Vienna), Margaretha Rudas(Comprehensive Cancer Center Vienna), Ruth Exner(Comprehensive Cancer Center Vienna), Georg Pfeiler(Medical University of Vienna), Marija Balić(University of Pittsburgh), Edgar Petru(Medical University of Graz), AL Petzner(Medical University of Graz), Michael Hubalek(Innsbruck Medical University), V. Wette(Medical University of Graz), P. Sevelda, R. Jakesz(Comprehensive Cancer Center Vienna), M-KM Tea(Medical University of Graz), Christian F. Singer(Comprehensive Cancer Center Vienna), Herbert Stoeger(Medical University of Graz), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna)
Cited by 2
Related Papers
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Breast cancer
|The Lancet|2016|2.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k